ArticlePPAR research2010
Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?
Article in PPAR research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Evidence on the causal link between homocysteine and hypertension from a meta-analysis of 40 173 individuals implementing Mendelian randomization.Journal of clinical hypertension (Greenwich, Conn.) · 2019Pooled it
- Pooled it
- Propolis alleviates brain tissue damage and oxidative abnormalities in streptozotocin (STZ)-induced diabetes.Journal, genetic engineering & biotechnology · 2026Article
- Causal Relationship Between Various Vitamins and Different Diabetic Complications: A Mendelian Randomization Study.Food science & nutrition · 2025Article
- Serum homocysteine concentration as a marker for advanced diabetic nephropathy in a cohort of elderly patients.BMC endocrine disorders · 2023Article
- Review
- Hyperhomocysteinemia and its relations to conventional risk factors for cardiovascular diseases in adult Nigerians: the REMAH study.BMC cardiovascular disorders · 2021Article
- Association between plasma homocysteine and hypertension: Results from a cross-sectional and longitudinal analysis in Beijing's adult population from 2012 to 2017.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Toll-like receptor 4 mediates vascular remodeling in hyperhomocysteinemia.Molecular and cellular biochemistry · 2017Review
- Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology.International journal of ophthalmology · 2017Review
- High renal resistive index in hypertensive patients is also associated with serum homocysteine level.Clinical and experimental nephrology · 2015Article
- Signaling pathway genes for blood pressure, folate and cholesterol levels among hypertensives: an epistasis analysis.Journal of human hypertension · 2015Article
- Association between plasma homocysteine and progression of early nephropathy in type 2 diabetic patients.International journal of clinical and experimental medicine · 2015Article
- Hyperhomocysteinemia is an independent predictor of long-term clinical outcomes in Chinese octogenarians with acute coronary syndrome.Clinical interventions in aging · 2015Article
- Article
- Association of homocysteinaemia with hyperglycaemia, dyslipidaemia, hypertension and obesity.Cardiovascular journal of Africa · 2013Article
- Article
- Homocysteine inhibits adipogenesis in 3T3-L1 preadipocytes.Experimental biology and medicine (Maywood, N.J.) · 2011Article
- Effect of homocysteine thiolactone on structure and aggregation propensity of bovine pancreatic insulin.The protein journal · 2011Article
- Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy.Biochemical and biophysical research communications · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Dysfunction of macro- and microvessels is a major cause of morbidity and mortality in patients with cardio-renovascular diseases such as atherosclerosis, hypertension, and diabetes. Renal failure and impairment of renal function due to vasoconstriction of the glomerular arteriole in diabetic nephropathy leads to renal volume retention and increase in plasma homocysteine level. Homocysteine, which is a nonprotein amino acid, at elevated levels is an independent cardio-renovascular risk factor. Homocysteine induces oxidative injury of vascular endothelial cells, involved in matrix remodeling through modulation of the matrix metalloproteinase (MMP)/tissue inhibitor of metalloproteinase (TIMP) axis, and increased formation and accumulation of extracellular matrix protein, such as collagen. In heart this leads to increased endothelial-myocyte uncoupling resulting in diastolic dysfunction and hypertension. In the kidney, increased matrix accumulation in the glomerulus causes glomerulosclerosis resulting in hypofiltration, increased renal volume retention, and hypertension. PPARgamma agonist reduces tissue homocysteine levels and is reported to ameliorate homocysteine-induced deleterious vascular effects in diabetes. This review, in light of current information, focuses on the beneficial effects of PPARgamma agonist in homocysteine-associated hypertension and vascular remodeling in diabetes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.